In one trial involving patients with uncontrolled hypertension already on 2–3 antihypertensive medications, weekly subcutaneous administration of IONIS-AGT-LRx for six weeks resulted in a mean reduction of plasma AGT levels by 69%, coupled with a significant reduction in SBP by 10.6 mmHg and DBP by 7.3 mmHg compared to placebo (18). The gene discussed is AGT; the disease is hypertensive disorder.